Live price temporarily unavailable.
Connect Biopharma Holdings (CNTB) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $26.0M | $64.0K |
| Growth (year over year) | — | — | — | — | −99.8% |
| Operating income | −$98.1M | −$119.3M | −$69.1M | −$22.5M | −$58.1M |
| Operating margin | — | — | — | −86.2% | −90740.6% |
| Net income | −$202.3M | −$118.1M | −$62.1M | −$15.6M | −$55.5M |
| Net margin | — | — | — | −60.0% | −86687.5% |
| EPS (diluted) | −$3.88 | −$2.15 | −$1.13 | −$0.28 | −$1.00 |
| Balance sheet | |||||
| Cash and equivalents | $267.7M | $78.9M | $105.7M | $78.2M | $38.3M |
| Total assets | $291.1M | $174.0M | $127.4M | $101.3M | $56.1M |
| Total liabilities | $18.8M | $16.5M | $25.9M | $9.12M | $14.1M |
| Shareholders' equity | $272.3M | $158.4M | $101.5M | $92.2M | $42.0M |
| Cash flow | |||||
| Operating cash flow | −$84.3M | −$101.5M | −$47.7M | −$23.6M | −$51.2M |
| Capital expenditure | $3.83M | $4.41M | $81.0K | $750.0K | $434.0K |
| Free cash flow | −$88.2M | −$105.9M | −$47.8M | −$24.4M | −$51.6M |
| Share buybacks | $566.0K | $0 | $0 | — | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.22M | — | $0 | $48.0K | $16.0K | — | $169.0K | $2.77M |
| Growth (year over year) | — | — | — | −99.8% | −98.7% | — | — | +5666.7% |
| Operating income | −$13.8M | — | −$11.4M | −$13.4M | −$17.7M | — | −$19.6M | −$17.6M |
| Operating margin | −1135.8% | — | — | −27966.7% | −110481.3% | — | −11601.8% | −636.0% |
| Net income | −$12.9M | — | −$10.3M | −$12.9M | −$17.2M | — | −$19.4M | −$17.3M |
| Net margin | −1056.3% | — | — | −26872.9% | −107500.0% | — | −11478.1% | −624.4% |
| EPS (diluted) | −$0.23 | — | −$0.19 | −$0.23 | −$0.31 | — | −$0.34 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $97.2M | $78.2M | $47.7M | $40.6M | $37.8M | $38.3M | $46.0M | $27.0M |
| Total assets | — | $101.3M | $92.7M | $82.7M | $67.4M | $56.1M | $60.1M | $43.5M |
| Total liabilities | — | $9.12M | $9.79M | $11.4M | $12.0M | $14.1M | $17.4M | $16.6M |
| Shareholders' equity | $100.6M | $92.2M | $82.9M | $71.3M | $55.4M | $42.0M | $42.6M | $26.9M |
| Cash flow | ||||||||
| Operating cash flow | −$13.0M | — | −$9.96M | −$12.6M | −$17.4M | — | −$16.0M | −$15.9M |
| Capital expenditure | $147.0K | — | $81.0K | $303.0K | $34.0K | — | $0 | $0 |
| Free cash flow | −$13.2M | — | −$10.0M | −$12.9M | −$17.4M | — | −$16.0M | −$15.9M |
From Connect Biopharma Holdings's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Connect Biopharma Holdings in our feed yet.